Long noncoding RNAs (lncRNAs) are involved in diabetes related diseases. However, the role of lncRNAs in the pathogenesis of type 2 diabetes with macrovascular complication (DMC) has seldomly been recognized. This study screened lncRNA profiles of leukocytes from DMC patients and explored protective role of lncRNA LYPLAL1-DT in endothelial cells (EC) under high glucose (HG) and inflammatory conditions (IS). Between DMC and healthy controls, 477 differential expression lncRNAs (DE-lncRNAs) were identified. The enrichment and pathway analysis showed that most of the DE-lncRNAs belonged to inflammatory, metabolic, and vascular diseases. A total of 12 lncRNAs was validated as significant DE-lncRNAs in expanding cohorts. Furthermore, these DE-lncRNAs were shown to be significantly related to hypoxia, HG, and IS in EC, especially lncRNA LYPLAL1-DT. LYPLAL1-DT overexpression results in the promotion of the proliferation, and migration of EC, as well as an elevation of autophagy. Overexpressed LYPLAL1-DT reduces the adhesion of monocytes to EC, boosts anti-inflammation, and suppresses inflammatory molecules secreted in the medium. Mechanistically, LYPLAL1-DT acts as competing endogenous RNA (ceRNA) by downregulating miR-204-5p, therefore enhancing SIRT1 and protecting EC autophagy function; thus, alleviating apoptosis. Finally, exosome sequencing revealed LYPLAL1-DT expression was 4 times lower in DMC cells than in healthy samples. In general, we identified LYPLAL1-DT having protective effects on EC as ceRNA mediated through the miR-204-5p/SIRT1 pathway. Therefore, it inhibits the autophagy of EC as well as modulating systemic inflammation. This approach could be regarded as a new potential therapeutic target in DMC.
TNF-α through activation of serum amyloid antigen 3 [8]. Studies investigating the link between IncRNAs and the development of diabetic complications have just begun [4]. Advances in sequencing and microarray technology enable the identification of large numbers of putative IncRNA loci and accelerate the progress within this field of research [9, 10]. Although several studies have focused on the correlation of IncRNA and vascular diseases [11–13], the role and characteristics of vascular abnormalities in diabetes caused by IncRNAs involved in hyperglycose and inflammation remain poorly understood [11, 14–17]. In the present study, we screened differentially expressed IncRNAs in circulating leukocytes isolated from diabetic macrovascular complicated individuals using RNA sequencing. We identified new IncRNAs related to DMC abnormal endothelial cells and further explored the protective effects of IncRNA LYLPLA1-1-DT as a ceRNA to inhibit miR-204-5p and upregulate SIRT1 in order to promote autophagy of endothelial cells (EC), as well as ameliorate inflammation of EC. These results reveal a novel IncRNA as a potential diagnostic marker and therapeutic target for DMC treatment in clinical practice.

RESULTS
Transcriptomic profiles in patients with diabetic macrovascular complications

The transcriptome sequencing in the discovery cohorts composed of 6 patients diagnosed with DMC and 6 health controls was used to determine the transcriptomic profiles. The data process flow chart is shown in Fig. 1a. The information of the DMC participants in both the discovery and the expanded cohorts are shown in Table 1, and demonstrates that most of the clinical characteristics were not significantly different between the two cohorts. Thus, the IncRNAs selected in the discovery cohort are reliably validated in the expanded cohort.

First, we described the transcriptomic profiles of DMC to identify the critical genes and IncRNAs in the DMC patients. A total of 14,978 IncRNAs and 17,172 mRNAs were detected in leukocytes from the DMC patients. Of these, 9235 IncRNAs have been registered in databases and defined as known. Out of the 9235 IncRNA’s, 4647 were upregulated, and 4588 were downregulated. The other 5743 IncRNAs were identified for the first time and were defined as either upregulated (3379) or downregulated (2364) novel IncRNAs. After optimization using an adjusted p value (threshold of <0.05) and fold change >2, we identified 477 significantly differentially expressed (DE) IncRNAs (DMC-IncRNAs) (Table S2), among which 245 were downregulated and 232 were upregulated (Fig. 1b). The top 20 DMC- IncRNAs are shown in Table 2. We further analyzed the different biotypes of the 477 DE-IncRNAs. The results indicated that 172 IncRNAs (36.1%) were antisense, 253 (53.0%) were intergenic (lincRNA), and 52 (10.9%) belonged to other types (sense-overlapping or sense-intronic) (Fig. 1c, Table S3). Furthermore, 798 DMC- mRNAs were found by similar optimization (Table S4), with 491 downregulated and 307 upregulated (Fig. S1a). Both DMC- IncRNA and DMC-mRNA were distinguishable within DMC patients and the healthy controls by hierarchical clustering (Figs. 1d, 5b) and principal content analysis (Figs. 1e, 5c). This data clearly illustrates a distinguishable differential expression profile of the leukocytes between DMC patients and the healthy controls.

Features of DE- IncRNAs and mRNAs identified in patients with DMC

The Gene Ontology (GO) enrichment analysis was applied to classify DMC patients’ DE- IncRNAs and DE-mRNAs. Under the biological process category, metabolic process, single organism process, response to stimulus, and cellular process were the top 4 DE- IncRNAs; similar items were found for the DE-mRNAs (Figs. 2a, S2). Under the molecular function category, both DE- IncRNAs and DE-mRNAs showed the highest percentages in catalytic activity and signal transducer activity items (Figs. 2a, S2). The top 20 items for DE-IncRNA demonstrated that most biological processes involved metabolic processes (17/20, 85%) (Fig. 2b). The highest molecular function is binding including RNA, DNA, and protein binding (Fig. 2c). These results imply that DE-IncRNAs identified from the DMC patients are involved in transcription regulation.

We structured co-expression networks to determine if IncRNAs are associated with IncRNAs or mRNAs. There were 509 genes involved in our co-expression networks consisting of 117 IncRNAs and 392 mRNAs (Fig. S3), with 7 IncRNAs and 18 mRNAs harboring more than 10 related genes in the CNC network. The top 10 IncRNAs and mRNAs with the number of genes to which they are related are shown in Table 3. In this CNC network, IncRNAs ENSG00000279463, MSTRG.39819, and ENSG00000228063 were the top 3 IncRNAs with the greatest number of related genes (35, 20, and 18) (Fig. 2d–f). The related genes such as TOMM5, and MYLK have been reported to have implications in diabetes [18], and PDLIM1 and CAMK2G were found to be related to atherosclerosis [19]. We also analyzed the characteristics of 9059 transcripts of novel IncRNAs identified in DMC patients. Most novel IncRNA transcripts harbored 2 exons (7060, 77.93%) (Fig. S4a). The lengths of most of the novel IncRNAs (71.91%) were less than 2000 bp (Fig. S4b). The conservation analysis in humans indicated that more than half (61.3%) had conservation scores (CS) less than 0.1 and 6.77% less than 0.01 between humans and other species (Fig. S4c). The distribution of chromosomal transcripts demonstrated that novel IncRNAs were primarily distributed on chr1 to chr6, and that most IncRNAs with low CS in humans were from the same chromosome (Fig. S5). These results reflect that IncRNAs in leukocytes may have an important effect on DMC.

Validation measurement of DE-IncRNAs in expanding groups

To confirm the DE-IncRNAs, we independently detected 16 IncRNAs in the validation group of DMC patients (n = 46) and healthy controls (n = 36) via real-time PCR. The expression levels of these IncRNAs in the validation cohort are shown in Fig. 3a. Of the 16 tested IncRNAs, 12 IncRNAs (75%) displayed dramatically different expression levels between the DMC and the healthy control groups; 4 IncRNAs were downregulated, and the others were upregulated in DMC. Nine novel IncRNAs and 3 known IncRNAs were positively confirmed. In addition, 8 IncRNAs belonged to the IncRNA, whereas 4 IncRNAs belonged to the antisense group (Table 4). Comparing the validation results and sequencing data revealed that most IncRNAs (75%, 12/16) displayed similar trends, with 10 IncRNAs exhibiting the same significantly positive results as observed in the sequencing data (Fig. S6). Among the 12 significantly different expression levels of IncRNAs, 8 IncRNAs harbor predicted target genes (Table S5).

We sought to identify potential orthologs of our selected IncRNAs by comparing their sequences with previously identified murine IncRNAs. Of the 12 validation-positive IncRNA, 8 (66.67%) exhibited orthologous sequences in the mouse genome (Table 5). Thus, these validated IncRNAs exhibited comparable conservation in humans and mice, which could lead to the use of a mouse model to directly investigate IncRNA biomarkers.

DE-IncRNAs response to HG and IS conditions in EC

The pathological changes of DMC are primarily due to higher serum glucose levels inducing abnormal metabolism, consequently influencing the functions and homeostasis of ECs [20–22]. A better understanding of IncRNAs response in EC under HG and IS is essential. Therefore, we tested the expression of 10 IncRNAs which are positively validated and exhibited the same significant trend as observed in the sequencing data within the HUVEC cell line. As shown in Figs. 3b, S7a, 3 IncRNAs exhibited increased levels after a 12 h and 24 h treatment with 25 mM, and 30 mM of glucose, respectively. LncRNA ENSG00000228063 was significantly downregulated after a 24 h treatment with HG in ECs (Figs. 3b, S7a).
Fig. 1 Characteristics of lncRNAs transcription in type 2 diabetes macrovascular complication. 

a A schematic illustration of the procedure to identify and define lncRNAs in the leukocytes of DMC patients. 

Healthy control (n = 6) and DMC (n = 6) 

Map reads to HG19 human genome 

Filtering: Long transcript filter (> 1 exon; > 200bp), Coding potential filter(CNCI, CPC, PFAM, and CPAT) 

14,978 lncRNAs: 9,235 known lncRNAs and 5,743 novel lncRNAs 

b Differentially expressed lncRNAs were identified from a Volcano plot showing data from DMC diabetes patient (n = 6) relative to healthy controls (n = 6). The vertical black lines correspond to 2-fold up and downregulations, respectively; and the horizontal black line represents a p value of 0.05. The red and green points in the plots represent the differentially expressed genes with statistical significance of the upregulation and downregulation of lncRNA, respectively. 

c Pie chart representations shows the proportion of DMC lncRNAs that are transcribed as antisense (blue), intergenic (orange), or other types (grey). 

d Differential lncRNA expression profiles were the hierarchical cluster was analyzed and shown as a heatmap. 

e Principal component analysis shows similar results also presented as a heatmap.
Based on the “metabolic memory,” which is defined as a phenomenon that the vasculature can remember transient hyperglycemia for quite an extended period even after the reestablishment of normoglycemia [23], we tested if there was a metabolic memory of these 4 lncRNAs in ECs. The results illustrated that the IncRNA MSTRG.122492 and MSTRG.3528 were significantly upregulated, and ENSG00000228063 was dramatically downregulated (Fig. 3c). We also performed HO and IS treatment on ECs to mimic the environment of the pathological metabolic memory of these 4 lncRNAs in ECs. The results showed that the expression of IncRNA MSTRG.3528 was significantly higher after a 12 h HO stimulus, the others exhibited no change (Fig. S7b). The expression of IncRNA MSTRG.74858 and ENSG00000228063 markedly decreased after a 6 h TNF-α stimulus, the others exhibited no change (Fig. S7b). The results showed that the expression of IncRNA MSTRG.3528 was significantly higher after a 12 h TNF-α treatment. MSTRG.3528 was downregulated after a 12 h treatment with TNF-α.

Table 1. Clinical characteristics of included patients of type 2 diabetes with macrovascular complication (DMC) in discovery cohorts (n = 6) and in validation cohorts (n = 46).

| Items          | DMC in discovery cohorts (n = 6) | DMC in validation cohorts (n = 46) |
|----------------|----------------------------------|-----------------------------------|
| Age (years)    | 55.50 ± 5.82                     | 56.70 ± 7.89                      |
| Sex (male%)    | 83.33%                           | 81.43%                            |
| BMI (kg/m2)    | 23.92 ± 1.24                     | 25.66 ± 3.13                      |
| Fasting glucose (mmol/L) | 7.51 ± 3.05 | 8.36 ± 3.64 |
| HbA1c (mmol/L) | 8.45 ± 1.72                      | 8.50 ± 1.93                       |
| Total cholesterol (mg/dL) | 5.10 ± 0.90 | 10.68 ± 51.76 |
| Fasting triglycerides (mg/dL) | 1.96 ± 0.99 | 2.14 ± 2.20 |
| HDL (mg/dL)    | 1.14 ± 0.39                      | 4.65 ± 29.46                      |
| LDL (mg/dL)    | 3.26 ± 0.70                      | 2.55 ± 0.87                       |

Table 2. The top 20 IncRNA with significantly differential expression in white blood cell from diabetes with macrovascular complication (DMC) and health control (C).

| Gene               | C normalize | DMC normalize | Log2 FC | FDR   | Up/Down | Biotype |
|--------------------|-------------|---------------|---------|-------|---------|---------|
| ENSG00000273338    | 109.992     | 10.1978       | -3.43107 | 3.52E-12 | down    | antisense |
| MSTRG.74858        | 82.0596     | 5.99718       | -3.77432 | 8.23E-12 | down    | linc    |
| MSTRG.179846       | 1146.59     | 289.948       | -1.98349 | 1.10E-11 | down    | antisense |
| ENSG00000270069    | 441.771     | 78.9949       | -2.48347 | 1.03E-10 | down    | linc    |
| MSTRG.159146       | 41.0073     | 1.86011       | -4.46242 | 1.48E-09 | down    | antisense |
| MSTRG.131944       | 2338.92     | 790.908       | -1.56426 | 8.50E-08 | down    | antisense |
| MSTRG.103146       | 630.434     | 189.15        | -1.73681 | 1.60E-07 | down    | antisense |
| MSTRG.80841        | 1.10689     | 23.3297       | 4.39759  | 3.55E-07 | up       | linc    |
| MSTRG.182419       | 92.9662     | 17.2915       | -2.42665 | 6.15E-07 | down    | linc    |
| MSTRG.159131       | 27.583      | 1.69268       | -4.0264  | 1.23E-06 | down    | linc    |
| MSTRG.187859       | 186.565     | 48.1136       | -1.95516 | 5.75E-06 | down    | linc    |
| MSTRG.106807       | 3095.66     | 1060.73       | -1.54518 | 5.76E-06 | down    | antisense |
| ENSG00000251022    | 1004.1      | 401.354       | -1.32295 | 6.08E-06 | down    | antisense |
| MSTRG.111791       | 29.3953     | 129.086       | 2.13468  | 1.02E-05 | up       | linc    |
| MSTRG.95088        | 12.1535     | 0.16631       | -6.19132 | 1.70E-05 | down    | linc    |
| MSTRG.116382       | 324.357     | 107.277       | -1.59624 | 2.31E-05 | down    | linc    |
| ENSG00000224307    | 38.2435     | 171.609       | 2.16584  | 5.80E-05 | up       | linc    |
| MSTRG.30000        | 75.0362     | 242.855       | 1.69444  | 6.61E-05 | up       | linc    |
| ENSG00000269902    | 88.1519     | 12.6132       | -2.80506 | 6.66E-05 | down    | linc    |
| MSTRG.183281       | 353.29      | 137.464       | -1.3618  | 6.86E-05 | down    | antisense |
Fig. 2  Bioinformatic analysis via enrichment analysis of GO terms for DMC-IncRNAs and co-expression networks for DMC-IncRNAs and mRNAs. 

a  GO analysis of DMC-IncRNAs within biological processes, molecular functions, and cellular components. 

b  The top 20 GO terms of lncRNAs enriched in biological processes.

c  The top 20 GO terms of lncRNAs enriched in molecular function.

d-f  The co-expression network of 3 lncRNAs including ENSG00000279463, MSTRG.39819 and ENSG00000228063.
Dysfunctional HUVECs promote vascular inflammation by expressing inflammation cytokines and surface adhesion molecules involved in DMC development. We collected the media of EC-OE under HG and analyzed the concentrations of the secreted cytokines. The results illustrate that the inflammatory molecule IL-1β (Fig. 4g) and the adhesion molecule ICAM-1 decreased (Fig. 4h); conversely, anti-inflammation molecules IL-10 and IL-13 were increased (Fig. 4i) in the EC-OE group and under HG conditions. Consistent with the high level of ICAM-1 in the cell culture media, the overexpression of LYPLAL1-DT significantly suppressed the adhesion of monocyte THP-1 cells onto the HG-treated HUVEC monolayers (Fig. 4j). These results suggest that LYPLAL1-DT plays a significant role in ameliorating the inflammatory conditions in ECs treated with HG.

**LYPLAL1-DT affected SIRT1 expression by acting as a ceRNA sponging miR-204-5p**

To explore the molecular mechanism of LYPLAL1-DT in the protection of EC, we were able to predict the miRNAs and the corresponding target genes using the bioinformatics tools TargetScan and miRcode. Upon analysis 13 miRNAs with a higher score were detected and found that 3 were upregulated and 2 were downregulated miRNAs in EC-OE compared to the control (Fig. S8). We chose miR-204-5p, the most significantly downregulated miRNA (Fig. 5a) in the EC-OE of LYPLAL1-DT to investigate its function. The miR-204-5p mimic remarkably suppresses the luciferase activity of wild type LYPLAL1-DT, compared to either the mutant or empty vector controls (Fig. 5d). The results demonstrated that the mimic miR-204-5p significantly suppresses the luciferase activity of wild type LYPLAL1-DT, compared to either the mutant or empty vector controls (Fig. 5d). We detected 9 target genes of miR-204-5p that were predicted using STARBASE via real-time PCR (Fig. S9), then were upregulated and 2 were downregulated miRNAs in EC-OE compared to the control (Fig. 5a). Further results of the RIP assay showed that LYPLAL1-DT, miR-204-5p, and SIRT1 bind to Ago2 (Fig. 5j), confirming that LYPLAL1-DT functions as a competing endogenous RNA (ceRNA) regulating the expression and function of SIRT1 via inhibition with miR-204-5p. SIRT1 is an important gene related to autophagy and apoptosis. Autophagy detected by acridine orange staining showed that LYPLAL1-DT increased the number of autophagy cells under HG condition, and miR-204-5p mimic decreased the number of autophagy cells (Fig. 5k). The protein level of LC3 II/I, the marker of autophagy, showed similar results (Fig. 5l). The apoptotic body under HG conditions demonstrated that LYPLAL1-DT decreased the number of TUNEL positive cells under HG conditions. Meanwhile, the transfection of miR-204-5p mimic significantly reversed the apoptosis level (Fig. 5m). Therefore, our results indicated that IncRNA LYPLAL1-DT inhibits miR-204-5p, consequently upregulating the expression of SIRT1. Furthermore, promoting autophagy, attenuating apoptosis levels in order to alleviate HG injury, and exerting protective effects on ECs.

**LYPLAL1-DT from leukocytes may exert protective effects on HUVEC via exosome transportation**

Exosomes regulate the biological functions of recipient cells via RNA transfer. Since LYPLAL1-DT was discovered in leukocytes, we hypothesized that LYPLAL1-DT was transmitted to HUVECs via exosomes. The serum exosomes of DMC patients and healthy controls were extracted, and RNA-sequencing was performed to confirm this hypothesis. The purified exosomes were detected by transmission electron microscopy (TEM) (Fig. 6a), NTA (Fig. 6b), and Western blot (Fig. 6c) using the positive exosome protein markers TSG101 and Alix. The RNA sequencing data showed that DE-IncRNAs (Fig. 6d, e) and DE-mRNAs (Fig. S10a, b) were found between exosomes derived from DMC and control serum, with LYPLAL1-DT having the most significantly different expression levels of the IncRNAs, harboring trends similar to the results found in leukocytes (Fig. 6f). We also detected that the leukocyte cell surface marker CD11b+ is positively expressed in exosomes (Fig. 6c), proving that exosomes may originate from leukocytes. Thus, we treated HUVEC using exosomes collected from DMC patients’ serum and healthy controls and detected miR-204-5p levels, cell viability, and migration ability. As expected, miR-204-5p levels were significantly lower in the control group than in the DMC group (Fig. 6g), while cell viability (Fig. 6h) and migration ability (Fig. 6i) of HUVECs were abbreviated in the DMC group. This data confirmed that expression of LYPLAL1-DT within the exosomes might be derived from the leukocytes affecting the ECs and protecting them from dysfunction.

**DISCUSSION**

In the present study, we constructed the transcription profiles of circulating leukocyte IncRNAs and mRNAs in DMC patients and further selected and investigated the molecular mechanisms of a novel IncRNA LYPLAL1-DT having protective effects under pathological conditions. We identified 477 IncRNAs harboring significant differences between patients with diabetic macrovascular complications and healthy controls. This data is more than a microarray analysis of differentially expressed genes screened from the transcriptome of endothelial cells induced by high glucose [24]. Functional analysis and IncRNA-mRNA network analysis showed that it contained many genes that have been reported to be related to diabetes and vascular diseases, such as TOMM5, MYLK, PDLIM1, and CAMK2G [25]. Next, we validated 12 IncRNAs in an expanding cohort. Pathological conditions that were adversely simulated showed that 4 IncRNAs were correlated with EC injury. Finally, IncRNA LYPLAL1-DT was selected and showed protective effects on ECs by combining to miR-204-5p as a ceRNA, thereby regulating the expression of SIRT1, enhancing autophagy, and alleviating EC inflammation. These results strongly suggest that circulating IncRNAs in leukocytes can be an important target for further studies of diabetic vascular complications. Meanwhile, abnormal expression of IncRNA in leukocytes affects ECs, including the adhesion of macrophages, similar to the reports that show IncRNA in the secreted bodies of ECs can adjust to the polarization effect of macrophages [26]. Upon further detection, it was also found that LYPLAL1-DT in exosomes from the serum of DMC patients are derived from leukocytes and is expressed at lower levels than in healthy controls and is similar in leukocytes. All

---

**Table 3.** The top 10 lncRNAs and mRNAs with numbers of related genes in co-expression network.

| Gene             | Biotype | Target gene counts |
|------------------|---------|--------------------|
| ENSG00000279463  | IncRNA  | 35                 |
| POLR2K           | mRNA    | 24                 |
| APP              | mRNA    | 21                 |
| RAC1             | mRNA    | 20                 |
| MSTRG.39819      | IncRNA  | 17                 |
| ENSG00000228063  | IncRNA  | 17                 |
| RHOA             | mRNA    | 17                 |
| GNGT2            | mRNA    | 16                 |
| CDC42            | mRNA    | 15                 |
| MAPK3            | mRNA    | 15                 |
Fig. 3  Validation of lncRNAs in DMC patients and lncRNAs expression levels induced by high glucose and TNF-α in HUVEC (DMC n = 46, healthy control n = 36). a 12 of the 16 lncRNAs showed significant difference in expression levels between the DMC patients (n = 46) and the healthy controls (n = 36) analyzed by real-time PCR. b The lncRNAs expression in HUVEC after treated with 25 mM glucose for 12 h and 24 h. c The lncRNAs expression in HUVEC after being induced by TNF-α for 12 h and 24 h. "NS": no significant difference; ** indicated significant difference with p < 0.01 and *** indicated p < 0.001.
results confirmed that IncRNAs in circulating leukocytes are crucial to the pathogenesis of DMC. Furthermore, LYPLAL1-DT is an important and potential new target for DMC research.

EC stabilization is a pivotal event in the development of diabetes-associated vascular diseases [3]. Sustained high blood glucose in diabetes will continuously stimulate blood vessels, leading to endothelial injury, further stimulating mononuclear cells to accumulate within the blood vessel wall; thus, accompanied by inflammation, and eventually leading to the occurrence of cardiovascular disease [27]. LncRNAs have emerged as critical regulators in a variety of EC biological or pathological processes. Yan B et al. reported that lncRNA-MIAT is involved in angiogenesis regulators in a variety of EC biological or pathological processes.

Table 4. The results of analysis by the categorical features of 16 lncRNAs which were chosen in validation cohorts. "**" marked the validation positive lncRNA.

| Categorical features | LncRNA | Ratio of lncRNA with significant difference |
|----------------------|--------|--------------------------------------------|
| Known lncRNA         | ENSG00000269902*, ENSG00000224307*, ENSG00000228063*, ENSG00000260244, ENSG00000274767 | 3/5 (60.00%) |
| Novel lncRNA         | MSTRG.122492*, MSTRG.74858*, MSTRG.95088*, MSTRG.159327*, MSTRG.30000*, MSTRG.131944*, MSTRG.152898*, MSTRG.63013*, MSTRG.3528*, MSTRG.159131, MSTRG.169545 | 9/11 (81.82%) |
| LncRNA               | ENSG00000269902*, ENSG00000224307*, MSTRG.122492*, MSTRG.74858*, MSTRG.95088*, MSTRG.30000*, MSTRG.63013*, MSTRG.3528*, MSTRG.159131, MSTRG.169545 | 8/10 (80.00%) |
| Antisense lncRNA     | ENSG00000228063*, ENSG00000274767, MSTRG.159327*, MSTRG.131944*, MSTRG.152898* | 4/5 (80.00%) |

Table 5. The information of 12 lncRNAs positively validated in the expanding cohort in present study and their potential orthologous sequences comparing with mouse data.

| LncRNA               | Novel/known | The log2 value in the RNA-seq data | Orthologous sequence with mouse |
|----------------------|-------------|-----------------------------------|--------------------------------|
| ENSG00000269902      | known       | −2.81                             | chr3:58,478,307-58,478,532     |
| ENSG00000224307      | known       | 2.17                              | chr11:121,806,938-121,808,036  |
| ENSG00000228063      | known       | −1.22                             | chr11:121,806,938-121,808,036  |
| MSTRG.122492         | novel       | −3.65                             | chr2:45,237,395-45,239,069     |
| MSTRG.74858          | novel       | −3.77                             | chr5:143,473,978-143,503,533   |
| MSTRG.95088          | novel       | −6.19                             | chr2:45,237,395-45,239,069     |
| MSTRG.159327         | novel       | 1.81                              | chr5:143,473,978-143,503,533   |
| MSTRG.30000          | novel       | 1.69                              | chr2:91,023,089-91,023,445     |
| MSTRG.131944         | novel       | −1.56                             | chr3:136,106,245-136,114,883   |
| MSTRG.152898         | novel       | 2.91                              | chr4:118,424,930-118,425,109   |
| MSTRG.63013          | novel       | 1.73                              | chr7:23,644,824-23,660,240     |
| MSTRG.3528           | novel       | 2.64                              | chr7:23,644,824-23,660,240     |

Of LYPLAL1-DT could decrease the adhesion of monophages onto the surface of ECs, enhancing the secretion of anti-inflammatory cytokines IL-10 and IL-13, which is further evidence of the protective effects of EC [31]. These findings suggest that IncRNAs are involved in regulating endothelial cells in the case of diabetes-induced vascular injury and are an important member in the regulation of diabetic macrovascular complications.

In recent years, accumulating evidence highlights a growing list of IncRNAs related to glucose homeostasis and diabetic complications. The molecular mechanisms of IncRNAs can be used as ceRNA in order to regulate target genes by acting as miRNA inhibitors, thus regulating the expression of protein-coding genes [32]. CeRNA plays a vital role in regulating the expression of hyperglycemic response genes. For example, IncRNA ca7-4 ceRNA of miR877-3p and miR5680 promotes autophagy and apoptosis of vascular ECs induced by high glucose [11]. In our study, novel IncRNA LYPLAL1-DT was found to regulate the target gene SIRT1 by acting as a ceRNA of miR-204-5p. SIRT1 is an anti-autophagy factor that can reduce cell death [33], as well as regulate the apoptosis of ECs through the mTOR pathway [34]. It is one of the most important roles in vascular biology and atherogenesis [35]. For instance, SIRT1 can also protect ECs from high glucose induced injury [33]. In the current study, we found SIRT1 is the target gene of LYPLAL1-DT, therefore elevating autophagy levels, thus decreasing apoptosis, inflammation, and monocyte adhesion of ECs. These results are similar to previous reports that SIRT1 inhibits monocyte adhesion to the vascular endothelium [36], and is involved in the inhibitory effects of endothelial cellular apoptosis [37]. More importantly, we confirmed the most recent
Fig. 4  The location of LYPLAL1-DT and the biological function of LYPLAL1-DT in HUVEC. a The location of LYPLAL1-DT on the chromosome. b The Subcellular localization of LYPLAL1-DT in HUVEC. c Establishment of LYPLAL1-DT-overexpression cell line with a pLenti-GIII-CMV-CBH-GFP-2A-Puro vector being transfected into HUVEC was identified by real-time PCR. d, e CCK-8 assays were performed to determine the viability of LYPLAL1-DT-overexpressing cells treated with HG (25 mM) or induced by TNF-α for 12 h. f Transwell assays were used to investigate the migration of LYPLAL1-DT-overexpressing cells treated with HG (25 mM) or induced by TNF-α (100 ng/ml) for 12 h. g, h, i The HG-treated and TNF-α-induced cell culture medium were collected to detect the expression levels of cytokines, including IL-1β, ICAM-1, IL-10, and IL-13, using ELISA Kits. j LYPLAL1-DT-overexpression HUVECs were pretreated with HG or TNF-α as described above, then adhered Dil-stained THP-1 cells were visualized by fluorescence microscopy. *" indicated significant difference with p < 0.05, "**" indicated p < 0.01 and "***" indicated p < 0.001.
report that miR-204-5p/SIRT1 mediates inflammation and apoptosis in EC dysfunction under cyanidin-3-O-glucoside treatment [38]. Combined with the report that SIRT1/FoxO1 pathway enhances autophagy flux in order to prevent atherosclerosis and arterial thrombosis [39], we believe SIRT1 plays a critical role in DMC. Hence, we present evidence that LYPLAL1-DT effectively protects against vascular endothelial injury in diabetes associated complications via the LYPLAL1-DT–miR-204-5p/SIRT1 pathway.
There are still some limitations in our study. First, the number of expanded samples for verification is not very large, primarily due to our relatively strict enrollment conditions. We only accepted patients who were initially diagnosed with having diabetic macrovascular complications. Second, how IncRNAs from leukocytes regulate EC function is still largely unknown, although we found that IncRNA LYL1-DT is also present in serum exosomes, with a similar downregulation trend as seen in leukocytes. These exosomes positively expressed leukocytic markers, and partly demonstrates that leukocytes are the primary source of serum exosomes. Moreover, we confirmed that exosomes with lower LYL1-DT could decrease cell viability and migration of ECs. Finally, this study lacks further research on the function of LYL1-DT using an animal model due to the very low conservation of LYL1-DT between humans and mice, as shown in Table 5 and Fig. S7. The species-specific effect of LYL1-DT in DMC remains to be further elucidated. Nevertheless, our observations underscore the importance of LYL1-DT in DMC using human cells.

CONCLUSION

In general, we identified 12 DE-IncRNAs related to DMC, among which IncRNA LYL1-DT was identified to be transmitted from leukocytes to ECs via exosomes and have protective effects on EC as ceRNA mediated through the miR-204-5p/SIRT1 pathway. Therefore, inhibiting EC autophagy as well as modulating systemic inflammation. This approach could be regarded as a new potential therapeutic target in DMC.

METHODS

Subjects
Human blood samples collected from the Department of Endocrinology, Chinese PLA General Hospital, were grouped into either the discovery cohort with healthy control (CTR, n = 6), type 2 diabetes mellitus with macrovascular complication (DMC, n = 6), a validation cohort with healthy control (CTR, n = 36), or type 2 diabetes mellitus with macrovascular complication (DMC, n = 46) assessed by clinic examination. All consenting adult subjects (18–65 years old) with no past medical history were consecutively enrolled between July 2016 and April 2018. The whole blood samples were subsequently collected separately in tubes containing RNA after overnight fasting for 10 to 14 h. The subjects in the healthy control group were: (1) healthy with a negative diagnosis of DMC as defined by the World Health Organization (WHO) and with normal blood biochemical indexes; (2) free from all endocrine disease, and (3) aged 18–65 years old without a gender bias. Exclusion criteria were similar to our previous study [40]. The detailed grouped information of all patients were shown in Table 1. This study was approved by the Ethics Committee of Chinese PLA General Hospital (Permitted No. S2016-147-03) and all patients were given informed consent.

Blood samples collection, exosome extraction, RNA sequencing and analysis
The whole blood sample was collected after fasting for 10–14 h, and total RNA was extracted from peripheral leukocytes as previously reported [40]. Exosomes derived from DMC patients’ serum were extracted via PEG precipitate method via a VEXTM Exosome Isolation Reagent (Vazyme, Nanjing, China). The RNA sequencing process, investigation flow, and data analysis design and methods were similar to our previous work and are shown in Fig. 1A. RNA sequencing was performed by Annoroad Gene Tech. Co., Ltd.

Cell culture and high glucose, hypoxia, and inflammatory stimulus
Endothelial cell (EC) line human umbilical vein endothelial cells (HUVECs) were purchased from the Shanghai Institute of Cell Biology of the Chinese Academy of Sciences (Shanghai, China) and cultured in RPMI 1640 medium (Corning) at 37 °C with 5% CO2, and supplemented with 10% fetal bovine serum (Vistech). Cells were cultured with a media consisting of 25/30 mM d-glucose (high glucose, HG) or 5 mM d-glucose and 20 mM mannitol (Equilibrium osmotic pressure) (normal glucose, NG). Hypoxia treatment was proceeded by culture cell under 37 °C with 5% CO2. The inflammatory stimulus was performed by adding TNF-α at a concentration of 10 ng/mL. For metabolism memory detection, the cells were first treated with 25 mM glucose for 24 h first, then cultured in a normal medium with a glucose concentration for 72 h. At the end of treatment, the expression levels of the IncRNAs were determined.

RNA extraction and real-time PCR
For further validation of IncRNA expression from the RNA-sequencing results, a total of 16 IncRNA were measured by real-time PCR in independent expanding cohorts of healthy control (n = 36), and DMC (n = 46) groups. The full primer list is presented in Supplementary Table S1. Total RNA extraction and PCR were performed as outlined in our previous report [40]. The 2-ΔΔCT method was used to quantify the relative expression of each IncRNA, using β-actin as an internal control. The relative expression of each examined gene was determined in triplicates. Differences in the IncRNA expressions among the groups were evaluated with a one-way analysis of variance (ANOVA) using SPSS 18.0 software. A significant difference was considered to be P < 0.05.

RNA samples from cultured EC were extracted using an RNA isolation Reagent (Vazyme, Nanjing, China). Complementary DNA (cDNA) from 2 μg total RNA was synthesized using 5X All-In-One RT MasterMix (ABM, Zhejiang, China). The amplification reaction volume was 20 μL, and contained 10 μL EvaGreen 2X qPCR MasterMix (ABM, Zhejiang, China), 1 μL cDNA, 2 μL amplification primers, and 7 μL ddH2O. Real-time PCR measured the expression levels of the predicted miRNAs and targeted genes in EC. A similar process was used for the peripheral leukocytes. The cDNA of the miRNA was synthesized using a miRNA 1st Strand CDNA Synthesis Kit (Vazyme, Nanjing, China), and real-time PCR was performed using miRNA Universal SYBR qPCR MasterMix (Vazyme, Nanjing, China). The primers for each gene are listed in Supplementary Table S2.

Construction of IncRNA LYL1-DT overexpression in an EC line
The overexpression of LYL1-DT in HUVECs and the corresponding control cells (OC) were constructed using plent-Gili-CMV-CBH-GFP-2A-Puro vector (ABM, Zhejiang, China). Cells were transfected for 24 h with a recombinant lentivirus and cultured for 72 h. The transfection efficacy was verified by GFP expression and detected by Real-time PCR.

Cell transfection
Cells were transfected with miR-204-5p mimic and a negative control (HANBIO, Shanghai, China). MiR-204-5p mimic was transfected at a final concentration of 50 nM via an RNAfet reagent (HANBIO, Shanghai, China), following the manufacturer’s instructions.

X. Zhu et al.

Cell Death Discovery (2022) 8:245
Cell viability, transwell assay, and Western blot

The viability and migration of HUVECs were assessed using CCK8 (Vazyme, Nanjing, China), a transwell assay, and a Western blot as performed in our previous studies [18]. The primary antibodies used for Western blot analysis were LC3 (CST), Caspase 3 (CST), β-actin (CST), SIRT1 (CST), Alix (CST), and TSG101 (CST).

Fig. 6 LYPLAL1-DT were transferred from leukocytes to HUVEC via exosomes in DMC patients. a Morphology of leukocytes-derived exosomes were shown by TEM. b Leukocyte-derived exosomes were observed to be between 30 and 120 nm in size analyzed by NTA. c Western Blot was used to examine exosome biomarker ALIX and TSG101, and the leukocyte surface marker CD11b. d, e Differentially expressed IncRNAs were identified from a Volcano plot and hierarchiical cluster analysis, shown as a heatmap (DMC n = 6, healthy control n = 9). f RNA-sequencing of DMC patients-derived exosomes and DMC patients’ leukocytes shows a similar trend of LYPLAL1-DT expression level. g The expression of miR-204-5p in HUVECs increased when treated with exosomes derived from DMC patients’ serum compared with control. Exosomes derived from DMC patients’ serum significantly decreased cell viability and migration of HUVEC compared with controls detected by (h) CCK8 and (i) Transwell assays.
Luciferase assay
To explore the role of the competing endogenous RNA LYLPL1-DT in ECs, we cloned the 3’-untranslated regions (UTR) of LYLPL1-DT downstream of the Renilla luciferase gene to generate RLuc- LYLPL1-DT wild type vector (WT) and the corresponding mutant type vector (MUT); thus, using the firefly luciferase gene as an internal reference. For the luciferase reporter assays, HUVECs were plated in 24-well culture plates, and then transfected with either the WT or the MUT construct with and without miRNA mimic or negative control mimic. Luciferase activities were measured using a Dual Luciferase Reporter Assay System (Vazyme, Nanjing, China), and every transfected well was analyzed in triplicate. The RLuc-SIRT1 wild type vector (WT) was generated to detect relative luciferase expression, following the above experimental steps, in order to discover the relations between miR-204-5p and SIRT1.

HUVEC-monoocyte adhesion and cytokines detection
To detect monocyte-endothelial interactions, in vitro static cell adhesion assays were performed. Human monocyte THP-1 cells were labeled via the fluorescent dye DiI (YEASEN, Shanghai, China). The cells were then co-cultured with HG-treated and TNF-α-stimulated HUVEC in a 6-well plate for 30 min. After washing with PBS three times, the fluorescence signal (red) of the adherent THP-1 cells was quantified under a fluorescence microscope. Cytokines in the cell culture medium were analyzed using ProcartaPlex Multiplexing Immunoassay kit (ebiScience, USA) using a Luminex 200 (Luminex, USA). Results were calculated using the ProcartaPlex Analyst 1.0 software.

Apoptosis detection and RNA immunoprecipitation assay (RIP)
The apoptosis level of HG-treated and TNF-α-stimulated HUVEC cells was detected by a TUNEL BrightGreen Apoptosis Detection Kit (Vazyme, Nanjing, China).

RIP was conducted using a Magna RIP RNA-Binding Protein Immunoprecipitation Kit (Millipore, Massachusetts, USA). Briefly, HUVECs were lysed and incubated with magnetic beads conjugated with AGO2 antibodies. After washing with a wash buffer, immunoprecipitated RNA was detected by real-time PCR.

Acridine orange staining
The HUVEC cells were plated into the confocal dish. After HG treated for 12 h, cells were covered by Acridine orange for 30 min, then washed 3 times by PBS, 5 min each time. The fluorescence signal of the cells was quantified under a fluorescence microscope.

Statistical analysis
Unless otherwise stated, all experiments were performed at a minimum of triplicates. Statistical analysis was performed using SPSS 19.0 software (SPSS Inc., USA). The data is represented as the mean ± SEM. Comparisons between groups were made using a student’s t test between two groups or a one-way ANOVA. Statistically significant differences were set as a P < 0.05.

DATA AVAILABILITY
The datasets during and/or analysed during the current study available from the corresponding author on reasonable request (The sequencing data of DMC is in the process of uploading to GEO).

REFERENCES
1. Cho NH, Shaw JE, Karuranga S, Huang Y, da Rocha Fernandes JD, Ohhogg AW, et al. IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pr. 2018;138:271–81.
2. Hammes HP, Feng Y, Pfister F, Brownlee M. Diabetic retinopathy: targeting vaso regression. Diabetes. 2011;60:9–16.
3. Sharma A, Rickly L, Stefanovic N, Tate M, Ritchie RH, Ward KW, et al. The nuclear factor (erythroid-derived 2)/like 2 (NFE2) activator dNKO4 protects against diabetes-induced endothelial dysfunction. Cardiovasc Diabetol. 2017;16:33.
4. Feng SD, Yang JH, Yao CH, Yang SS, Zhu ZM, Wu D, et al. Potential regulatory mechanisms of IncRNA in diabetes and its complications. Biochim Biophys Acta. 2017;2015:361–7.
5. Sun Q, Hao Q, Prasanth KV. Nuclear long noncoding RNAs: key regulators of gene expression. Trends Genet. 2018;34:142–57.
6. Yao C, Wang Y, Zhang H, Feng W, Wang Q, Shen D, et al. IncRNA TNXA-PS1 modulates Schwann cells by functioning as a competing endogenous RNA following nerve injury. J Neurosci. 2018;38:6574–85.
7. Zhu L, Zhong Q, Yang T, Xiao X. Improved therapeutic effects on diabetic foot by human mesenchymal stem cells expressing MALAT1 as a sponge for microRNA-205-5p. Aging (Albany NY). 2019;11:2236–45.
8. Puthanveetil P, Chen S, Feng B, Gautam A, Chakrabarti S. Long non-coding RNA MALAT1 regulates hyperglycaemia induced inflammatory process in the endothelial cells. J Cell Mol Med. 2015;19:1418–25.
9. Sun C, Xue L, Zhu Z, Zhang F, Yang R, Yuan X, et al. Insights from IncRNAs Profiling of MIN6 Beta Cells Undergoing Inflammation. Mediators Inflamm. 2016;2016:2971506.
10. Wang X, Chang X, Zhang P, Fan L, Zhou T, Sun K. Aberrant expression of long non-coding RNAs in newly diagnosed type 2 diabetes indicates potential roles in chronic inflammation and insulin resistance. Cell Physiol Biochem. 2017;43:2367–76.
11. Zhao X, Su L, He X, Zhao B, Miao J. Long noncoding RNA CA7-4 promotes autophagy and apoptosis via sponging MIR87-3P and MIR5680 in high glucose-induced vascular endothelial cells. Autophagy. 2020;16:70–85.
12. Michalik KM, You X, Manavski Y, Doddaballapur A, Zornig M, Braun T, et al. Long noncoding RNA MALAT1 regulates endothelial cell function and vessel growth. Circ Res. 2014;114:1389–97.
13. Luo L, Ji LD, Cai JJ, Feng M, Zhu M, Hu SP, et al. Microarray analysis of long noncoding RNAs in female diabetic peripheral neuropathy patients. Cell Physiol Biochem. 2018;46:1209–17.
14. Khzya N, Khor M, DiStefano PV, Wang L, Matic L, Hedlin U, et al. Regulation of CCL2 expression in human vascular endothelial cells by a neighboring divergently transcribed long noncoding RNA. Proc Natl Acad Sci USA. 2019;116:16410–9.
15. Jue N, Heumuller AW, Fouani Y, Dimmeler S. Long non-coding RNAs in vascular biology and disease. Vasc Pharm. 2019;114:13–22.
16. Biswas S, Chakrabarti S. Increased extracellular matrix protein production in chronic diabetic complications: implications of non-coding RNAs. Noncoding RNA. 2019;5:30.
17. Bell RD, Long X, Lin M, Bergmann JH, Nanda V, Cowan SL, et al. Identification and initial functional characterization of a human vascular cell-enriched long non-coding RNA. Arterioscler Thromb Vasc Biol. 2014;34:1249–59.
18. Cao Q, Liu Y, Wu Y, Hu C, Sun L, Wang J, et al. Profilin 2 promotes growth, metastasis, and angiogenesis of small cell lung cancer through cancer-derived exosomes. Aging (Albany NY). 2020;12:25981–99.
19. Li W, Hu B, Li GL, Zhao XQ, Xin BZ, Lin JX, et al. Heterozygote genotypes at rs2222823 and rs2811712 SNP loci are associated with cerebral small vessel disease in Han Chinese population. CNS Neurosci Ther. 2012;18:558–65.
20. Milanesi E, Manda G, Dobre M, Codrici E, Neagoe IV, Popescu BD, et al. Distinctive under-expression profile of inflammatory and redox genes in the blood of elderly patients with cardiovascular disease. J Inflamm. 2021;14:429–42.
21. Li W, Sasse KC, Baguinyov Y, Ward SM, Perrino BA. Contractile protein expression and phosphorylation and contractility of gastric smooth muscles from obese patients and patients with obesity and diabetes. J Diabetes Res. 2018:2018:8473874.
22. Jiao M, Li J, Zhang Q, Xu X, Li R, Dong P, et al. Identification of four potential biomarkers associated with coronary artery disease in non-diabetic patients by gene co-expression network analysis. Front Genet. 2020;11:542.
23. Man HSL, Sukumar AN, Lam GC, Turgeon PJ, Yan MS, Ku KH, et al. Angiogenic patterning by STEEL, an endothelial-enriched long noncoding RNA. Proc Natl Acad Sci USA. 2018;115:2401–6.
24. Singh KK, Mantella LE, Pan Y, Quan A, Sabongui S, Sandhu P, et al. A global profile of glucose-sensitive endothelial-expressed long non-coding RNAs. Can J Physiol Pharmac. 2016;94:1007–14.
25. Chen J, Meng Y, Zhou J, Zhuo M, Ling F, Zhang Y, et al. Identifying candidate genes for Type 2 Diabetes Mellitus and obesity through gene expression profiling in multiple tissues or cells. J Diabetes Res. 2013;2013:970435.
26. Huang C, Han J, Wu Y, Li S, Wang Q, Lin W, et al. Exosomal MALAT1 derived from oxidized low-density lipoprotein-treated endothelial cells promotes M2 macrophage polarization. Mol Med Rep. 2018;18:509–15.
27. Rask-Madsen C, King GL. Vascular complications of diabetes: mechanisms of injury and protective factors. Cell Metab. 2013;17:20–33.
28. Yan B, Yao L, Liu JY, Li XM, Wang XQ, Li YJ, et al. IncRNA-MIAT regulates micro-vascular dysfunction by functioning as a competing endogenous RNA. Circ Res. 2015;116:1143–56.
29. Zheng W, Guo J, Liu ZS. Effects of metabolic memory on inflammation and fibrosis associated with diabetic kidney disease: an epigenetic perspective. Clin Epigenetics. 2021;13:87.
30. Liao Y, Gou L, Chen L, Zhong X, Zhang D, Zhu H, et al. NADPH oxidase 4 and endothelial nitric oxide synthase contribute to endothelial dysfunction mediated by histone methylations in metabolic memory. Free Radic Biol Med. 2018;115:383–94.
31. Garcia-Vaz E, McNeilly AD, Berglund LM, Ahmad A, Gallagher JR, Dutius Andersson AM, et al. Inhibition of NFAT signaling restores microvascular endothelial function in diabetic mice. Diabetes. 2020;69:424–35.

32. Luo Y, Fang Z, Ling Y, Luo W. LncRNA-H19 acts as a ceRNA to regulate HE4 expression by sponging miR-140 in human umbilical vein endothelial cells under hyperglycemia with or without alpha-Mangostin. Biomed Pharmacother. 2019;118:109256.

33. Han WM, Chen XC, Li GR, Wang Y. Acacetin protects against high glucose-induced endothelial cells injury by preserving mitochondrial function via activating Sirt1/Sirt3/AMPK signals. Front Pharm. 2020;11:607796.

34. Pal PB, Sonowal H, Shukla K, Srivastava SK, Ramana KV. Aldose reductase regulates hyperglycemia-induced HUVEC death via SIRT1/AMPK-alpha1/mTOR pathway. J Mol Endocrinol. 2019;63:11–25.

35. Sosnowska B, Mazidi M, Penson P, Gluba-Brzozka A, Rysz J, Banach M. The sirtuin family members SIRT1, SIRT3 and SIRT6: Their role in vascular biology and atherogenesis. Atherosclerosis. 2017;265:275–82.

36. Lee SJ, Baek SE, Jang MA, Kim CD. SIRT1 inhibits monocyte adhesion to the vascular endothelium by suppressing Mac1 expression on monocytes. Exp Mol Med. 2019;51:1–12.

37. Tang H, Li K, Zhang S, Lan H, Liang L, Huang C, et al. Inhibitory effect of paeonol on apoptosis, oxidative stress, and inflammatory response in human umbilical vein endothelial cells induced by high glucose and palmitic acid induced through regulating SIRT1/FOXO3a/NF-kappaB pathway. J Interferon Cytokine Res. 2021;41:11–24.

38. Wang Z, Zhang M, Wang Z, Guo Z, Wang Z, Chen Q. Cyanidin-3-O-glucoside attenuates endothelial cell dysfunction by modulating miR-204-5p/SIRT1-mediated inflammation and apoptosis. Biofactors. 2020;46:803–12.

39. Wu Q, Hu Y, Jiang M, Wang F, Gong G. Effect of autophagy regulated by Sirt1/FoxO1 pathway on the release of factors promoting thrombosis from vascular endothelial cells. Int J Mol Sci. 2019;20:4132.

40. Liu Y, Du X, Cui J, Li C, Guo M, Lv J, et al. A genome-wide analysis of long noncoding RNAs in circulating leukocytes and their differential expression in type 1 diabetes patients. J Diabetes Res. 2020;2020:9010314.

ACKNOWLEDGEMENTS
The authors thank AiMi Academic Services (www.aimieditor.com) for English language editing and review services.

AUTHOR CONTRIBUTIONS
All authors were responsible for drafting the article and revising it for important intellectual content. They all approved the version to be published.

FUNDING
This work was supported by National Natural Science Foundation of China (Nos. 31970512, 31772545).

COMPETING INTERESTS
The authors declare no competing interests.

ETHICS APPROVAL AND CONSENT TO PARTICIPATE
This study was conducted on the basis of the Declaration of Helsinki, after obtaining the written informed consent of the participating patients and the approval of the Ethics Committee of Chinese PLA General Hospital (Permitted No. S2016-147-03).

CONSENT FOR PUBLICATION
Once the manuscript is accepted, we approve it to be published in Cardiovascular Diabetology.

ADDITIONAL INFORMATION

SUPPLEMENTARY INFORMATION
The online version contains supplementary material available at https://doi.org/10.1038/s41420-022-01019-z.

Correspondence and requests for materials should be addressed to Xiaoyan Du.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© The Author(s) 2022